Literature DB >> 797484

Carbohydrate metabolism in liver disease.

D G Johnston, K G Alberti.   

Abstract

Most forms of liver disease are probably associated with impaired gluconeogenesis, although hypoglycaemia is rarely an important clinical feature. Blood concentrations of the gluconeogenic precursors, lactate, glycerol and alanine are elevated although, in certain situations, alanine levels may be decreased. Abnormal glucose tolerance is present in both acute and chronic liver disease, but is usually not of clinical importance. The mechanism of glucose intolerance remains uncertain, with diminished hepatocyte mass, portal diversion and insulin resistance the major postulates. Indeed, the importance of the liver in disposing of an oral glucose load, is still questioned. Both hyperinsulinism and hypoinsulinism are found in liver disease, with hyperinsulinism common in cirrhosis and acute viral hepatitis. This is accompanied by insulin resistance. The hyperinsulinism is probably due to defective hepatic clearance of insulin rather that to over-production. The cause of the insulin resistance remains to be established. Glucagon levels are raised and may contribute to this resistance. Growth hormone levels are also increased but are associated with low somatomedin levels and the role of growth hormone in insulin resistance is therefore questionable. Future developments include use of new animal models, studies of biopsy specimens and studies of hepatic hormone receptors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 797484     DOI: 10.1016/s0300-595x(76)80046-1

Source DB:  PubMed          Journal:  Clin Endocrinol Metab        ISSN: 0300-595X


  8 in total

1.  Diabetic ketoacidosis.

Authors:  D R Owens
Journal:  Ir J Med Sci       Date:  1979       Impact factor: 1.568

Review 2.  Metabolic response to malnutrition: its relevance to enteral feeding.

Authors:  A H Love
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

3.  Perspective in liver disease: An Irish experience.

Authors:  M J Whelton
Journal:  Ir J Med Sci       Date:  1979-12       Impact factor: 1.568

4.  C-peptide in non-alcoholic cirrhosis and hepatocellular carcinoma.

Authors:  K K Pun; P W Ho; R T Yeung
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

5.  A pilot study optimizing metabolomic and lipidomic acquisition in serum for biomarker discovery in nonalcoholic fatty liver disease.

Authors:  Dandan He; Yang Su; Duanyue Meng; Xinmiao Wang; Jun Wang; Hui Ye
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-10-09

6.  Glycerol clearance in alcoholic liver disease.

Authors:  D G Johnston; K G Alberti; R Wright; P G Blain
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

7.  Liver disease in patients with diabetes mellitus.

Authors:  K J Foster; A H Griffith; K Dewbury; C P Price; R Wright
Journal:  Postgrad Med J       Date:  1980-11       Impact factor: 2.401

8.  Insulin and glucagon production in experimental cirrhosis.

Authors:  A Alwmark; A Santos; V Mamlok; G H Greeley; J C Thompson
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.